Inhibitors of HIV-1 gene expression and transcription

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 871-882

  Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; ASCORBIC ACID; CEPHARANTHINE; CHRYSIN; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; EBSELEN; FRAMYCETIN; GENTAMICIN; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KANAMYCIN A; LEPTOMYCIN B; MESSENGER RNA; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; OLTIPRAZ; PENTOXIFYLLINE; PROTEIN INHIBITOR; REV PROTEIN; STAUROSPORINE; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEIN KINASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS REPLICATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

ANTI-HIV AGENTS; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; HIV-1; HUMANS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 2942615518     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388466     Document Type: Review

References (108)

1. Carpenter, C. C. J.; Cooper, D. A.; Fischl, M. A.; Gatell, J. M.; Gazzard, B. G.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S. G.; Richman, D. D.; Saag, M. S.; Schechter, M.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society-USA panel. JAMA 2000, 283, 381-390.
2. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5, 512-517.
3. Karn, J. Inhibitors of transcription and transactivation as anti-human immunodeficiency virus agents. In Antiretroviral Therapy; De Clercq, E.; Ed.; ASM Press: Washington, D.C., 2001; pp 105-128.
4. Baba, M. Cellular factors as targets for anti-human immunodeficiency virus therapy. In Antiretroviral Therapy; De Clercq, E.; Ed.; ASM Press: Washington, D.C., 2001; pp 191-217.
5. Osborn, L. S.; Kunkel, S.; Nabel G. J. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 1989, 86, 2336-2340.
6. Nabel, G.; Baltimore, D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (London) 1987, 32, 711-713.
7. Duh, E. J.; Maury, W. J.; Folks, T. M.; Fauci, A. S.; Rabson, A. B. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 1989, 86, 5974-5978.
8. Perkins, N. D.; Edwards, N. L.; Duckett, C. S.; Agranoff A. B.; Schmid, R. M; Nabel, G. J. A cooperative interaction between NF-κB and Sp1 is required for HIV-1 enhancer activation. EMBO J. 1993, 12, 3551-3558.
9. Perkins, N. D.; Agranoff, A. B.; Pascal, E.; Nabel, G. J. An interaction between the DNA-binding domains of RelA (p65) and Sp1 mediates human immunodeficiency virus gene activation. Mol. Cell. Biol. 1994, 14, 6570-6583.
10. Karn, J. Tackling Tat. J. Mol. Biol. 1999, 293, 235-254.
11. Laspia, M. S.; Rice, A. P.; Mathews, M.B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989, 59, 283-292.
12. Marciniak, R. A.; Sharp, P. A. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 1991, 10, 4189-4196.
13. Herrman, C. H.; Rice, A. P. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology 1993, 197, 601-609.
14. Herrman, C. H.; Rice, A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase Il: candidate for a Tat cofactor. J. Virol. 1995, 69, 1612-1620.
15. Marshall, N. F.; Price, D. H. Purification of p-TEFb, a transcription factor required for the transition into productive elongation. J. Bio. Chem. 1995, 270, 12335-12338.
16. Zhu, Y.; Pe'ery, T.; Peng, J.; Ramanathan, Y.; Marshall, N.; Marshall, T.; Amendt, B.; Mathews, M. B.; Price, D. H. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 1997, 11, 2622-2632.
17. Wei, P.; Garber, M. E.; Fang, S.-M.; Fischer, W. H.; Jones, K. A. A novel CDK-9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998, 92, 451-462.
18. Bieniasz, P. D.; Grdina, T. A.; Bogerd, H. P.; Cullen, B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 1998, 17, 7056-7065.
19. Garber, M. E.; Wei, P.; KewalRamani, V. N.; Mayall, T. P.; Herrmann, C. H.; Rice, A. P.; Littman, D. R.; Jones, K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 1998, 12, 3512-3527.
20. Zapp, M. L.; Green, E. R. Sequence-specific binding by the HIV-1 Rev protein. Nature (London) 1989, 342, 714-716.
21. Daly, T. J.: Cook, K. S.: Gary, G. S.: Maione, T. E.: Rusche, J. R. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature (London) 1989, 342, 816-819.
22. Pollard, V. W.; Malim, M. H. The HIV-1 Rev protein. Annu. Rev. Microbiol. 1998, 52, 491-532.
23. Baba, M.; Okamoto, M.; Makino, M.; Kimura, Y.; Ikeuchi, T.; Sakaguchi, T.; Okamoto, T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 1997, 41, 1250-1255.
24. Butera, S. T. Therapeutic targeting of human immunodeficiency virus type-1 latency: current realities and future scientific possibilities. Antiviral Res. 2000, 48, 143-176.
25. Emiliani, S.; Fischle, W.; Ott, M.; Van Lint, C.; Amella, C. A.; Verdin, E. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J. Virol. 1998, 72, 1666-1670.
26. Emiliani, S.; Van Lint, C.; Fischle, W.; Paras, P.; Ott, M.; Brady, J.: Verdin, E. A point mutation in the HIV-1 tat responsive element is associated with post-integration latency. Proc. Natl. Acad. Sci. USA 1996, 93, 6377-6381.
27. O'Brien, W. A.; Summer-Smith, M.; Mao, S.-U.; Sadeghi, S.; Zhao, J.-Q.; Chen, I. S. Y. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 1996, 70, 2825-2831.
28. Doranz, B. J.; Grovit-Ferbas, K.; Sharron, M. P.; Mao, S. H.; Goetz, M. B.; Daar, E. S.; Doms, R. W.; O'Brien, W. A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 1997, 186, 1395-1400.
29. Hamy, F.; Felder, E. R.; Heizman, G.; Lazdins, J.; Aboul-Ela, F.; Varani, G.; Karn, J.; Klimkait, T. An inhibitor of the Tat/TAR interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 1997, 94, 3548-3553.
30. Daelemans, D.; Schols, D.; Witvrouw, M.; Pannecouque, C.; Hatse, S.; Van Dooren, S.; Hamy, F.; Klimkait, T.; De Clercq, E.; Vandamme, A.-M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmaol. 2000, 57, 116-124.
31. Hamy, F.; Brondani, V.; Flörsheimer, A.; Stark, W.; Blommers, M. J. J.; Klimkait, T. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 1998, 37, 5085-5095.
32. Harry, F.; Gelus, N.; Zeller, M.; Lazdins, J. L.; Bailly, C.; Klimkait, T. Blocking HIV replication by targeting Tat protein. Chem. Biol. 2000, 7, 669-676.
33. Litovchick, A.; Evdokimov, A. G.; Lapidot, A. Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry 2000, 39, 2838-2852.
34. Cabrera, C.; Gutierrez, A.; Blanco, J.; Barretina, J.; Litovchick, A.; Lapidot, A.; Evdokimov, A. G.; Clotet, B.; Este, J.A. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. AIDS Res. Hum. Retroviruses 2000, 16, 627-634.
35. Parada, C. A.; Roeder, R. G. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature (London) 1996, 384, 375-378.
36. Mancebo, H. S. Y.; Lee, G.; Flygare, J.; Tomassini, J.; Luu, P.; Zhu, Y.; Peng, J.; Blau, C.; Hazuda, D.; Price, D.; Flores, O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 1997, 11, 2633-2644.
37. Zapp, M. L.; Stern, S.; Green, M. R. Small molecule that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 1993, 74, 969-978.
38. Wolff, B.; Sanglier, J.-J.; Wang, Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev- dependent mRNA. Chem. Biol. 1997, 4, 139-147.
39. Kudo, N.; Matsumori, N.; Taoka, H.; Fujiwara, D.; Schreiner, E.P.; Wolff, B.; Yoshida, M.; Horinouchi, S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 1999, 96, 9112-9117.
40. Legrand-Poels, S.; Vaira, D.; Pincemail, J.; Van de Vorst, A.; Piette, J. Activation of human immunodeficiency virus type 1 by oxidative stress. AIDS Res. Hum. Retroviruses 1990, 6, 1389-1397.
41. Staal, F. J. T.; Roederer, M.; Herzenberg, L. A.; Herzenberg, L.A. Intracellular thiols regulate activation of nuclear factor κB and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1990, 87, 9943-9947.
42. Schreck, R.; Rieber, P.; Baeuerle, P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-κB transcription factor and HIV-1. EMBO J. 1991, 10, 2247-2258.
43. Roederer, M.; Staal, F. J. T.; Raju, P. A.; Ela, S. W.; Herzenberg, L. A.; Herzenberg, L. A. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc. Natl. Acad. Sci. USA 1990, 87, 4884-4888.
44. Roederer, M.; Raju, P. A.; Staal, F. J. T.; Ela, S. W.; Herzenberg, L. A.; Herzenberg, L. A. N-Acetylcysteine inhibits latent HIV expression in chronically infected cells. AIDS Res. Hum. Retroviruses 1991, 7, 563-567.
45. Kalebic, T.; Kinter, A.; Poli, G.; Anderson, M. E.; Meister, A.; Fauci, A. S. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc. Natl. Acad. Sci. USA 1991, 88, 986-990.
46. Ho, W.-Z.; Douglas, S. D. Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res. Hum. Retroviruses 1992, 8, 1249-1253.
47. Nottet, H. S. L. M.; Moelans, I. I. M. D.; de Vos, N. M.; de Graaf, L.; Visser, M. R.; Verhoef, J. N-acetyl-L-cysteine-induced up-regulation of HIV-1 gene expression in monocyte-derived macrophage correlates with increased NF-κB DNA binding activity. J. Leukocyte Biol. 1997, 61, 33-39.
48. Akerlund, B.; Jarstrand, C.; Lindeke, B.; Sonnerborg, A.; Akerblad, A. C.; Rasool, O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur. J. Clin. Pharmacol. 1996, 50, 457-461.
49. Look, M. P.; Rockstroh, J. K.; Rao, G. S.; Barton, S.; Lemoch, H.; Kaiser, R.; Kupfer, B.; Sudhop, T.; Spengler, U.; Sauerbruch, T. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur. J. Clin. Invest. 1998, 28, 389-397.
50. Muller, F.; Svardal, A. M.; Nordoy, I.; Berge, R. K.; Aukrust, P.; Froland S. S. Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur. J. Clin. Invest. 2000, 30, 905-914.
51. Bergamini, A.; Capozzi, M.; Ghibelli, L.; Dini, L.; Salanitro, A.; Milanese, G.; Wagner, T.; Beninati, S.; Pesce, C. D.; Amici, C.; Rocchi, G. Cystamine potently suppress in vitro HIV-1 replication in acutely and chronically infected human cells. J. Clin. Invest. 1994, 93, 2251-2257
52. Ho, W.-Z.; Zhu, X.-H.; Lee, H.-R.; Cutilli, J. R.; Douglas, S. T. Cystamine inhibits HIV type 1 replication in cells of monocyte/macrophage and T cell lineages. AIDS Res. Hum. Retroviruses 1995, 11, 451-459.
53. Bergamini, A.; Ventura, L.; Mancino, G.; Capozzi, M.; Placido, R.; Salanitro, A.; Cappannoli, L.; Faggioli, E.; Stoler, A.; Rocchi, G. In vitro inhibition of the replication of human immunodeficiency virus type 1 by β-mercaptoethylamine (cysteamine). J. Infect. Dis. 1996, 174, 214-218.
54. Merin, J. P.; Matsuyama, M.; Kira, T.; Baba, M.; Okamoto, T. α-Lipoic acid blocks HIV-1 LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett. 1996, 394, 9-13.
55. Harakeh, S.; Jariwalla, R. J.; Pauling, L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7245-7249.
56. Harakeh, S.; Jariwalla, R. J. NF-κB-independent suppression of HIV expression by ascorbic acid. AIDS Res. Hum. Retroviruses 1997, 13, 235-239.
57. Israel, N.; Gougerot-Pocidalo, M. A.; Aillet, F.; Virelizier, J. Redox status of cells influences constitutive or induced NF-κB translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J. Immunol. 1992, 149, 3386-3393.
58. Tang, A.M.; Graham, N. M. H.; Semba, R. D.; Saah, A. J. Association between serum vitamin A and E levels and HIV-1 disease progression. AIDS 1997, 11, 613-620.
59. Allard, J. P.; Aghdassi, E.; Chau, J.; Tam, C.; Kovacs, C. M.; Salit, I. E.; Walmsley, S. L. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS 1998, 12, 1653-1659.
60. Prochaska, H. J.; Yeh, Y.; Baron, P.; Polsky, B. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 1993, 90, 3953-3957.
61. Prochaska, H. J.; Bornmann, W. G.; Baron, P.; Polsky, B. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo-[1,2-a]pyrazine, an in vivo metabolite of oltipraz. Mol. Pharmacol. 1995, 48, 15-20.
62. Parnham, M. J.; Graf, E. Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. Biochem. Pharmacol. 1987, 36, 3095-3102.
63. Baba M. Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res. 1997, 33, 141-152.
64. Matsuno, T.; Orita, K.; Edashige, K.; Kobuchi, H.; Sato, E. F.; Inouye, B.; Inoue, M.; Utsumi, K. Inhibition of active oxygen generation in guinea- pig neutrophils by biscoclaurine alkaloids. Biochem. Pharmacol. 1990, 39, 1255-1259.
65. Goto, M.; Zeller, W. P.; Hurley, R. M. Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats. J. Pharm. Pharmacol. 1991, 43, 589-591.
66. Kondo, Y.; Imai, Y.; Hojo, H.; Hashimoto, Y.; Nozoe, S. Selective inhibition of T-cell-dependent immune responses by bis-benzylisoquinoline alkaloids in vivo. Int. J. Immunopharmacol. 1992, 14, 1181-1186.
67. Okamoto, M.; Ono, M.; Baba, M. Potent inhibition of HIV-1 replication by an anti-inflammatory alkaloid, cepharanthine, in chronically infected monocyte cells. AIDS Res. Hum. Retroviruses 1998, 14, 1239-1245.
68. Okamoto, M.; Ono, M.; Baba, M. Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potential agent against HIV-1 encephalopathy. Biochem. Pharmacol. 2001, 62, 747-753.
69. Baba, M.; Okamoto, M.; Kashiwaba, N.; Ono, M. Anti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells. Antiviral Chem. Chemother. 2002, 12, 307-312.
70. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258, 607-613.
71. Kinter, A. L.; Poli, G.; Maury, W.; Folks, T. M.; Fauci, A. S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 1990, 64, 4306-4312.
72. Laurence, J.; Sikder, S. K.; Jhaveri, S.; Salmon, J. E. Phorbol ester-mediated induction of HIV-1 from a chronically infected promonocyte clone: blockade by protein kinase inhibitors and relationship to tat-directed trans-activation. Biochem. Biophys. Res. Commun. 1990, 166, 349-357.
73. Critchfield, J. W.; Ho, O.; Roberts, B.D.; Van Lint, C.; Verdin, E.; Butera, S. T. Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency. Antiviral Chem. Chemother. 1999, 10, 275-284.
74. Martiny-Baron, G.; Kazanietz, M. G.; Mischak, H.; Blumberg, P. M.; Kochs, G.; Hug, H.; Marme, D.; Schachtele. C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J. Biol. Chem. 1993, 268, 9194-9197.
75. Qatsha, K. A.; Rudolph, C.; Marme, D.; Schachtele, C.; May, W.S. Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl. Acad. Sci. USA 1993, 90, 4674-4678.
76. Fazely, F.; Dezube, B. J.; Allen-Ryan, J.; Perdee, A. B.; Ruprecht, R.M. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991, 77, 1653-1656.
77. Biswas, D. K.; Dezube, B. J.; Ahlers, C. M.; Pardee, A. B. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action. J. Acquir. Immune Defic. Syndr. 1993, 6, 778-786.
78. Biswas, D. K.; Ahlers, C. M.; Dezube, B. J.; Pardee, A. B. Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-κB induced gene expression. Mol. Med. 1994, 1, 31-43.
79. Navarro, J.; Punzón, M. C.; Pizarro, A.; Fernández-Cruz, E.; Fresno, M.; Muñoz-Fernández, M. A. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumor necrosis factor synthesis or nuclear factor-κB activation. AIDS 1996, 10, 469-475.
80. Clerici, M.; Piconi, S.; Balotta, C.; Trabattoni, D.; Capetti, A.; Fusi, M. L.; Ruzzante, S.; Longhi, R.; Colombo, M. C.; Moroni, M.; Milazzo, F. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-1 seropositive persons. J. Infect. Dis. 1997, 175, 1210-1215.
81. Dezube, B. J. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 1994, 18, 285-287.
82. Butera, S. T., Roberts, B. D.; Critchfield, J. W.; Fang, G.; McQuade, T.; Gracheck, S. J.; Folks, T. M. Compounds that target novel cellular components involved in HIV-1 transcription. Mol. Med. 1995, 1, 758-767.
83. Critchfield, J.W.; Butera, S. T.; Folks, T.M. Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res. Hum. Retroviruses 1996, 12, 39-46.
84. Critchfield, J. W.; Coligan, J. E.; Folks, T. M.; Butera, S. T. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc. Natl. Acad. Sci. USA 1997, 94, 6110-6115.
85. Pisen, T. L.; Ho, O.; Lee, G.; Butera, S. T. Spectrum of cdk-9 inhibitor activity against HIV-1 replication among various models of chronic and latent infection. Antiviral Chem. Chemother. 2001, 12 (Suppl. 1), 33-41.
86. Chao, S. H.; Fujinaga, K.; Marion, J. E.; Taube, R.; Sausville, E. A.; Senderowicz, A. M.; Peterlin, B. M.; Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 2000, 275, 28345-28348.
87. Hsu, M.-C.; Schutt, A. D.; Holly, M.; Slice, L. W.; Sherman, M. I.; Richman, D. D.; Potash, M. J.; Volsky, D. J. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991, 254, 1799-1802.
88. Hsu, M.-C.; Dhingra, U.; Earley, J. V.; Holley, M.; Keith, D.; Nalin, C. M.; Richou, A. R.; Schutt, A. D.; Tam, S. Y.; Potash, M. J.; Volsky, D. J.; Richman, D. D. Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. USA 1993, 90, 6395-6399.
89. Witvrouw, M.; Pauwels, R.; Vandamme, A.; Schols, D.; Reymen, D.; Yamamoto, N.; Desmyter, J.; De Clercq, E. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob. Agents Chemother. 1992, 36, 2628-2633.
90. Dunne, A. L.; Siregar, H.; Mills, J.; Crowe, S. M. HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429. J. Leukocyte Biol. 1994, 56, 369-373.
91. Braddock, M.; Cannon, P.; Muckenthaler, M.; Kingsman, A. J.; Kingsman, S. M. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. J. Virol. 1994, 68, 25-33.
92. Cupelli, L. A.; Hsu, M.-C. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J. Virol. 1995, 69, 2640-2643.
93. Turpin, J. A.; Buckheit, R. W.; Derse, D.; Hollingshead, M.; Williamson, K.; Palamone, C.; Osterling, M. C.; Hill, S. A.; Graham, L.; Schaeffer, C. A.; Bu, M.; Huang, M.; Cholody, W. M.; Michejda, C. J.; Rice, W. G. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrobial. Agents Chemother. 1998, 42, 487-494.
94. Fujiwara, M.; Okamoto, M.; Okamoto, M.; Watanabe, M.; Machida, H.; Shigeta, S.; Konno, K.; Yokota, T.; Baba, M. Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells. Antiviral Res. 1999, 43, 189-199.
95. Baba, M.; Okamoto, M.; Makino, M.; Kimura, Y.; Ikeuchi, T.; Sakaguchi, T.; Okamoto, T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 1997, 41, 1250-1255.
96. Baba, M.; Okamoto, M.; Kawamura, M.; Makino, M.; Higashida, T.; Takashi, T.; Kimura, Y.; Ikeuchi, T.; Tetsuka, T.; Okamoto, T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 1998, 53, 1097-1103.
97. Miyoshi, I.; Taguchi, H.; Kubonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shiraishi, Y.; Akagi, T. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 1982, 28, 219-228.
98. Okamoto, M.; Okamoto, T.; Baba, M. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob. Agents Chemother. 1999, 43, 492-497.
99. Witvrouw, M.; Daelemans, D.; Pannecouque, C.; Neyts, J.; Andrei, G.; Snoeck, R.; Vandamme, A.-M.; Balzarini, J.; Desmyter, J.; Baba, M.; De Clercq, E. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinoline derivatve K-12. Antiviral Chem. Chemother. 1998, 9, 403-411.
100. Okamoto, H.; Cujec, T. P.; Okamoto, M.; Peterlin, M.; Baba, M.; Okamoto, T. Inhibition of RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000, 272, 402-408.
101. Wang, X.; Miyake, H.; Okamoto, M.; Saito, M.; Fujiwasa, J.; Tanaka, Y.; Izumo, S.; Baba, M. Inhibition of the Tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinoline derivative K-37. Mol. Pharmacol. 2002, 61, 1-7.
102. Baba, M.; Okamoto, M.; Takeuchi, H. Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species. Antimicrob. Agents Chemother. 1999, 42, 2350-2355.
103. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Back, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 patients on highly active antiretroviral therapy. Science 1997, 278, 1295-1300.
104. Wong, J. K.; Hezareh, M.; Ganthard, H. F.; Havlir, D. V.; Ignacio, C. C.; Spina, C. A.; Richman, D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278, 1921-1925.
105. Zhang, L.; Ramratnam, B:, Tenner-Racz, K.; He, Y.; Vesanen, M.; Lewin, S.; Talal, A.; Racz, P.; Perelson, A. S.; Korber, B. T.; Markowitz, M.; Ho, D. D. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 1999, 340, 1605-1613.
106. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5, 512-517.
107. Ramratnam, B.; Mittler, J. E.; Zhang, L.; Boden, D.; Hurley, A.; Fang, F.; Macken, C. A.; Perelson, A. S.; Markowitz, M.; Ho, D. D. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 2000, 6, 82-85.
108. Blankson, J. N.; Persaud, D.; Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 2002, 53, 557-593.